

Datasheet: PIP021

BATCH NUMBER 160441

Description:	NATIVE INFLUENZA A H1N1 ANTIGEN
Name:	INFLUENZA A H1N1 ANTIGEN
Format:	Inactivated Pathogen
Product Type:	Antigen
Quantity:	1 ml

Product Details

Applications

This product has been reported to work in the following applications. This information is derived from testing within our laboratories, peer-reviewed publications or personal communications from the originators. Please refer to references indicated for further information. For general protocol recommendations, please visit www.bio-rad-antibodies.com/protocols.

	Yes	No	Not Determined	Suggested Dilution
ELISA	▪			
Haemagglutination	▪			

Where this product has not been tested for use in a particular technique this does not necessarily exclude its use in such procedures. Suggested working dilutions are given as a guide only. It is recommended that the user titrates the product for use in their own system using appropriate negative/positive controls.

Target Species	Viral
Product Form	Inactivated Influenza A H1N1 antigen - liquid
Preparation	Influenza strain A/New Caledonia/20/99 (H1N1) cultured in embryonated chicken eggs. Eggs are infected by injection into the allantoic chamber, incubated for 72 hours, and refrigerated overnight prior to harvest. Allantoic fluids are harvested from the eggs and pooled. The antigen preparation is inactivated by gamma radiation.
Buffer Solution	Phosphate buffered saline
Preservative Stabilisers	None present
Approx. Protein Concentrations	Current, batch-specific concentration 2.1 mg/ml
Product Information	Native influenza H1N1 antigen preparation is presented as semi-purified allantoic fluid from chicken eggs infected with New Caladonia 20/99 (H1N1) influenza A virus. Influenza

is an acute infection of the respiratory tract caused by the Influenza virus, of which there are several different types. Influenza A causes flu in birds and some mammals and is the most virulent of the influenza types, resulting in the most severe disease. Influenza infection in humans causes chills, fever, pharyngitis, muscle pain, headaches, coughing and weakness. The virus is transmitted through the air by coughs or sneezes or through saliva, nasal secretions, faeces and blood. Infection may occur through direct contact with infected bodily fluid or contaminated surfaces. Influenza viruses mutate rapidly, making vaccines less effective from one season to the next.

This particular strain of influenza is a reassortant virus that includes genetic components of the H1N1 influenza pandemic swine flu in a culture-adapted virus that has been selected for its qualities as a vaccine-producing strain. The live reassortant virus has passed safety testing in ferrets, in which it is attenuated for pathogenicity relative to wild-type A/California/4/2009 virus. Because A/California/4/2009 is identified as a variant strain of a pandemic virus, live derivatives must be handled under BSL2⁺ facilities and procedures.

Native influenza H1N1 antigen preparation (PIP021) contains a high concentration of viral antigens as well as some egg proteins from allantoic fluid.

Hemagglutination endpoint assay; 30720 HA Units/ml

Activity	40960 HA units/ml as determined by hemagglutination endpoint assay.
Instructions For Use	A precipitate may form upon thawing, due to high product concentration. Dilute prior to clarification or other manipulation.
References	1. Sakamoto, H. <i>et al.</i> (2015) A Novel Optical Biosensing System Using Mach-Zehnder-Type Optical Waveguide for Influenza Virus Detection. Appl Biochem Biotechnol. Oct 24. [Epub ahead of print]
Storage	Store at -70°C. Storage in frost-free freezers is not recommended. This product should be stored undiluted. Avoid repeated freezing and thawing as this may denature the protein.
Guarantee	Guaranteed until date of expiry. Please see product label.
Health And Safety Information	Material Safety Datasheet documentation #10518 available at: https://www.bio-rad-antibodies.com/SDS/PIP021 10518 This product has been rendered inactive by gamma irradiation. However this material should still be handled as infectious and should be disposed of appropriately.
Regulatory	For research purposes only

North & South America	Tel: +1 800 265 7376 Fax: +1 919 878 3751 Email: antibody_sales_us@bio-rad.com	Worldwide	Tel: +44 (0)1865 852 700 Fax: +44 (0)1865 852 739 Email: antibody_sales_uk@bio-rad.com	Europe	Tel: +49 (0) 89 8090 95 21 Fax: +49 (0) 89 8090 95 50 Email: antibody_sales_de@bio-rad.com	To find a
----------------------------------	---	------------------	---	---------------	---	------------------

batch/lot specific datasheet for this product, please use our online search tool at: bio-rad-antibodies.com/datasheets

'M393985:220125'

Printed on 19 Jan 2024

© 2024 Bio-Rad Laboratories Inc | [Legal](#) | [Imprint](#)